FR21C1004I2 - Utilisation de la proteinase ides (de s. pyogenes) pour le traitement des maladies autoimmunes et du rejet de greffe - Google Patents
Utilisation de la proteinase ides (de s. pyogenes) pour le traitement des maladies autoimmunes et du rejet de greffeInfo
- Publication number
- FR21C1004I2 FR21C1004I2 FR21C1004C FR21C1004C FR21C1004I2 FR 21C1004 I2 FR21C1004 I2 FR 21C1004I2 FR 21C1004 C FR21C1004 C FR 21C1004C FR 21C1004 C FR21C1004 C FR 21C1004C FR 21C1004 I2 FR21C1004 I2 FR 21C1004I2
- Authority
- FR
- France
- Prior art keywords
- treatment
- ides
- pyogenes
- proteinase
- autoimmune diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/2201—Streptopain (3.4.22.10)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/80—Antibody or fragment thereof whose amino acid sequence is disclosed in whole or in part
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0511769A GB0511769D0 (en) | 2005-06-09 | 2005-06-09 | Treatment |
GB0605781A GB0605781D0 (en) | 2006-03-22 | 2006-03-22 | Treatment |
PCT/EP2006/005454 WO2006131347A2 (fr) | 2005-06-09 | 2006-06-08 | Traitement |
Publications (2)
Publication Number | Publication Date |
---|---|
FR21C1004I1 FR21C1004I1 (fr) | 2021-03-26 |
FR21C1004I2 true FR21C1004I2 (fr) | 2022-01-14 |
Family
ID=36952007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR21C1004C Active FR21C1004I2 (fr) | 2005-06-09 | 2021-02-04 | Utilisation de la proteinase ides (de s. pyogenes) pour le traitement des maladies autoimmunes et du rejet de greffe |
Country Status (14)
Country | Link |
---|---|
US (1) | US8133483B2 (fr) |
EP (1) | EP1901773B1 (fr) |
JP (1) | JP5427409B2 (fr) |
CN (1) | CN105770871A (fr) |
AT (1) | ATE548049T1 (fr) |
AU (1) | AU2006256891B2 (fr) |
BE (1) | BE2021C505I2 (fr) |
CA (1) | CA2611646C (fr) |
ES (1) | ES2380950T3 (fr) |
FR (1) | FR21C1004I2 (fr) |
NL (1) | NL301089I2 (fr) |
PL (1) | PL1901773T3 (fr) |
PT (1) | PT1901773E (fr) |
WO (1) | WO2006131347A2 (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU1686302A (en) * | 2000-12-21 | 2002-07-01 | Shire Biochem Inc | Streptococcus pyogenes antigens and corresponding dna fragments |
EP2144681A4 (fr) * | 2007-05-04 | 2011-10-05 | Kurt G I Nilsson | Matériau pour la séparation d'une biomolécule |
EP2225273B1 (fr) | 2007-12-21 | 2012-05-23 | Roche Glycart AG | Essai de stabilité d'anticorps |
CN102308216B (zh) | 2009-02-09 | 2014-07-09 | 罗切格利卡特公司 | 免疫球蛋白糖基化模式分析 |
WO2010122545A1 (fr) * | 2009-04-22 | 2010-10-28 | Ofir Menashe | Micro-organisme comprenant des particules et ses utilisations |
GB201413240D0 (en) * | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
GB201502306D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
GB201502305D0 (en) * | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
AU2017214441B2 (en) * | 2016-02-04 | 2021-08-19 | Genovis Ab | New Streptococcal proteases |
US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
KR20220040476A (ko) * | 2019-08-01 | 2022-03-30 | 메모리얼 슬로안 케터링 캔서 센터 | 개선된 면역치료법을 위한 세포 및 이의 용도 |
TW202128744A (zh) | 2019-12-06 | 2021-08-01 | 美商再生元醫藥公司 | 抗vegf蛋白組合物及其製備方法 |
GB202007434D0 (en) * | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Methods |
GB202007431D0 (en) | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Cysteine protease |
US20230374083A1 (en) * | 2020-09-21 | 2023-11-23 | Shanghai Bao Pharmaceuticals Co., Ltd. | Pharmaceutical combination and use thereof |
EP4225382A2 (fr) | 2020-10-07 | 2023-08-16 | Asklepios Biopharmaceutical, Inc. | Administration de virus adéno-associés thérapeutiques de protéine associée à la fukkutine (fkrp) pour le traitement de la dystroglycanopathie. troubles comprenant la ceinture 21 du membre |
US20240189447A1 (en) | 2021-04-16 | 2024-06-13 | Asklepios Biopharmaceutical, Inc. | Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response |
EP4079848A1 (fr) | 2021-04-22 | 2022-10-26 | Genovis Ab | Enzyme de clivage d'immunoglobuline |
CN115998690A (zh) * | 2022-11-10 | 2023-04-25 | 上海泰昶生物技术有限公司 | 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6797263B2 (en) * | 2000-05-12 | 2004-09-28 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for achieving immune suppression |
GB0123400D0 (en) * | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
GB0130228D0 (en) | 2001-12-18 | 2002-02-06 | Hansa Medica Ab | Protein |
-
2006
- 2006-06-08 AU AU2006256891A patent/AU2006256891B2/en active Active
- 2006-06-08 PL PL06754207T patent/PL1901773T3/pl unknown
- 2006-06-08 PT PT06754207T patent/PT1901773E/pt unknown
- 2006-06-08 CA CA2611646A patent/CA2611646C/fr active Active
- 2006-06-08 US US11/921,770 patent/US8133483B2/en active Active
- 2006-06-08 WO PCT/EP2006/005454 patent/WO2006131347A2/fr active Application Filing
- 2006-06-08 JP JP2008515137A patent/JP5427409B2/ja active Active
- 2006-06-08 CN CN201610049256.0A patent/CN105770871A/zh active Pending
- 2006-06-08 EP EP06754207A patent/EP1901773B1/fr active Active
- 2006-06-08 AT AT06754207T patent/ATE548049T1/de active
- 2006-06-08 ES ES06754207T patent/ES2380950T3/es active Active
-
2021
- 2021-01-14 NL NL301089C patent/NL301089I2/nl unknown
- 2021-02-04 FR FR21C1004C patent/FR21C1004I2/fr active Active
- 2021-02-09 BE BE2021C505C patent/BE2021C505I2/fr unknown
Also Published As
Publication number | Publication date |
---|---|
FR21C1004I1 (fr) | 2021-03-26 |
WO2006131347A3 (fr) | 2007-05-31 |
PT1901773E (pt) | 2012-06-06 |
WO2006131347A2 (fr) | 2006-12-14 |
EP1901773B1 (fr) | 2012-03-07 |
ATE548049T1 (de) | 2012-03-15 |
US20100303781A1 (en) | 2010-12-02 |
CA2611646A1 (fr) | 2006-12-14 |
NL301089I1 (fr) | 2021-01-20 |
ES2380950T3 (es) | 2012-05-21 |
AU2006256891B2 (en) | 2011-08-04 |
JP2008542418A (ja) | 2008-11-27 |
NL301089I2 (nl) | 2021-02-04 |
US8133483B2 (en) | 2012-03-13 |
PL1901773T3 (pl) | 2012-09-28 |
CN105770871A (zh) | 2016-07-20 |
JP5427409B2 (ja) | 2014-02-26 |
AU2006256891A1 (en) | 2006-12-14 |
CA2611646C (fr) | 2015-08-11 |
BE2021C505I2 (fr) | 2021-05-31 |
EP1901773A2 (fr) | 2008-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR21C1004I2 (fr) | Utilisation de la proteinase ides (de s. pyogenes) pour le traitement des maladies autoimmunes et du rejet de greffe | |
MA31920B1 (fr) | 4-(4-cyano-2-thioaryle)-dihydropyrimidinone et son utilisation | |
FR22C1052I2 (fr) | Anticorps anti-cd19 humanises et leur utilisation dans le traitement des tumeurs, de la transplantation et des maladies auto-immunes | |
NO20091736L (no) | IL-17-reseptor A-antigenbindende proteiner | |
WO2008071418A3 (fr) | Traitement | |
UA96139C2 (uk) | Антитіло до нейропіліну-1 (nrp1) | |
WO2003048327A3 (fr) | Anticorps anti-cd45rb s'utilisant dans le traitement de maladies auto-immunes et de rejet de greffon | |
MX355256B (es) | Anticuerpos anti-il-17a/il-17f de reactividad cruzada y métodos de uso de los mismos. | |
EA201000424A1 (ru) | Антитела к il-23 | |
WO2005016127A3 (fr) | Reactifs peptidiques specifiques du prion | |
WO2006086799A3 (fr) | Reactifs de peptide specifiques au prion | |
EA200801180A1 (ru) | Селективные пептидные агонисты рецептора vpac2 | |
WO2008092905A3 (fr) | Activation spécifique d'un lymphocyte t régulateur et son utilisation pour le traitement de l'asthme, d'une maladie allergique, d'une maladie auto-immune, d'un rejet de greffe et pour une induction de tolérance | |
ATE389670T1 (de) | Selektive peptidische agonisten des vpac2- rezeptors | |
IL209338A0 (en) | Pharmaceutical compositions containing anti-cd-3 antibodies | |
PH12020551805A1 (en) | Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof | |
DE602005013650D1 (de) | Proteinhydrolysat zur behandlung von müdigkeit | |
SG162829A1 (en) | Humanised antibodies specific for nogo-a and pharmaceutical uses thereof | |
FR2889068B1 (fr) | Nouvelles fractions proteiques laitieres et leur utilisation pour la prevention ou le traitement des maladies inflammatoires chroniques | |
ATE412010T1 (de) | Selektive peptidische agonisten des vpac2- rezeptors | |
ATE442382T1 (de) | Ein die mam-domäne enthaltendes protein | |
FR2858234B1 (fr) | Nouvel agent anti-angiogenique et son utilisation, notamment dans le cadre du traitement des cancers | |
FR2856595B1 (fr) | Methodes et compositions pour le traitement de deficits cognitifs. | |
WO2006103472A3 (fr) | Facteur immunoregulateur soluble | |
UA97645C2 (ru) | АНТИТЕЛО, СПЕЦИФИЧЕСКИ СВЯЗЫВАЮЩЕЕ РЕЦЕПТОР ИНТЕРЛЕЙКИНА-6 ЧЕЛОВЕКА (hIL-6R) |